$HOOK
HOOKIPA Pharma Inc.

2022 Q1 Form 10-Q Financial Statement

#000155837022008855 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $1.445M $5.301M
YoY Change -72.74% 43.27%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.972M $4.310M
YoY Change 15.36% -14.14%
% of Gross Profit
Research & Development $16.62M $20.16M
YoY Change -17.58% 82.64%
% of Gross Profit
Depreciation & Amortization $1.078M $1.103M
YoY Change -2.27% 169.02%
% of Gross Profit
Operating Expenses $16.62M $20.16M
YoY Change -17.58% 24.78%
Operating Profit -$20.15M -$19.17M
YoY Change 5.09%
Interest Expense $243.0K $219.0K
YoY Change 10.96% 143.33%
% of Operating Profit
Other Income/Expense, Net $2.179M $1.934M
YoY Change 12.67% 33.38%
Pretax Income -$17.97M -$17.24M
YoY Change 4.23% 57.71%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$17.97M -$17.24M
YoY Change 4.23% 57.77%
Net Earnings / Revenue -1243.46% -325.18%
Basic Earnings Per Share -$0.40 -$0.53
Diluted Earnings Per Share -$0.40 -$0.53
COMMON SHARES
Basic Shares Outstanding 45.04M 32.77M
Diluted Shares Outstanding 45.04M 32.77M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $140.8M $127.7M
YoY Change 10.28% 22.2%
Cash & Equivalents $140.8M $128.1M
Short-Term Investments
Other Short-Term Assets $13.93M $7.700M
YoY Change 80.9% 83.33%
Inventory
Prepaid Expenses
Receivables $703.0K $4.300M
Other Receivables $15.62M $13.60M
Total Short-Term Assets $171.1M $153.3M
YoY Change 11.6% 27.01%
LONG-TERM ASSETS
Property, Plant & Equipment $17.10M $13.10M
YoY Change 30.53% -7.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.796M $3.500M
YoY Change -48.69% 218.18%
Total Long-Term Assets $24.63M $16.60M
YoY Change 48.39% 8.5%
TOTAL ASSETS
Total Short-Term Assets $171.1M $153.3M
Total Long-Term Assets $24.63M $16.60M
Total Assets $195.7M $169.9M
YoY Change 15.19% 24.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.708M $8.100M
YoY Change -17.19% 102.5%
Accrued Expenses $9.607M $5.400M
YoY Change 77.91% 22.73%
Deferred Revenue $10.70M
YoY Change
Short-Term Debt $3.375M $0.00
YoY Change
Long-Term Debt Due $0.00 $100.0K
YoY Change -100.0% -50.0%
Total Short-Term Liabilities $31.23M $20.10M
YoY Change 55.36% 30.52%
LONG-TERM LIABILITIES
Long-Term Debt $1.766M $4.900M
YoY Change -63.96% 25.64%
Other Long-Term Liabilities $2.474M $4.900M
YoY Change -49.51% -36.36%
Total Long-Term Liabilities $16.55M $9.800M
YoY Change 68.92% -15.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.23M $20.10M
Total Long-Term Liabilities $16.55M $9.800M
Total Liabilities $47.78M $29.90M
YoY Change 59.81% 10.74%
SHAREHOLDERS EQUITY
Retained Earnings -$240.7M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $147.9M $140.1M
YoY Change
Total Liabilities & Shareholders Equity $195.7M $169.9M
YoY Change 15.19% 24.93%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$17.97M -$17.24M
YoY Change 4.23% 57.77%
Depreciation, Depletion And Amortization $1.078M $1.103M
YoY Change -2.27% 169.02%
Cash From Operating Activities $1.733M -$14.40M
YoY Change -112.04% 101.92%
INVESTING ACTIVITIES
Capital Expenditures $1.828M $330.0K
YoY Change 453.94% -265.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.828M -$330.0K
YoY Change 453.94% 65.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $45.69M $125.0K
YoY Change 36450.4%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 75.29M 101.0K
YoY Change 74447.52% -107.89%
NET CHANGE
Cash From Operating Activities 1.733M -14.40M
Cash From Investing Activities -1.828M -330.0K
Cash From Financing Activities 75.29M 101.0K
Net Change In Cash 75.20M -14.63M
YoY Change -614.14% 69.87%
FREE CASH FLOW
Cash From Operating Activities $1.733M -$14.40M
Capital Expenditures $1.828M $330.0K
Free Cash Flow -$95.00K -$14.73M
YoY Change -99.35% 112.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45040022
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32766284
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001760542
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38869
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
HOOKIPA PHARMA INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-5395687
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
350 Fifth Avenue, 72nd Floor, Suite 7240
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10118
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
423000
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140825000
CY2022Q1 dei Country Region
CountryRegion
+43
CY2022Q1 dei City Area Code
CityAreaCode
1
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
890 63 60
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1682000
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q1 dei Trading Symbol
TradingSymbol
HOOK
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5538000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65921000
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
555000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
566000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1724000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
703000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6895000
CY2022Q1 hook Receivables Tax Research Premium Current
ReceivablesTaxResearchPremiumCurrent
15622000
CY2021Q4 hook Receivables Tax Research Premium Current
ReceivablesTaxResearchPremiumCurrent
14271000
CY2022Q1 hook Prepaid Expenses And Other Current Assets
PrepaidExpensesAndOtherCurrentAssets
13374000
CY2021Q4 hook Prepaid Expenses And Other Current Assets
PrepaidExpensesAndOtherCurrentAssets
14482000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
171079000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
102135000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
425000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17100000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16352000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5313000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5673000
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
90000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1796000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1370000
CY2022Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
24632000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
23910000
CY2022Q1 us-gaap Assets
Assets
195711000
CY2021Q4 us-gaap Assets
Assets
126045000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6708000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8762000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10696000
CY2022Q1 hook Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8725000
CY2021Q4 hook Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8880000
CY2022Q1 us-gaap Loans Payable Current
LoansPayableCurrent
3375000
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
2792000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
31228000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27654000
CY2022Q1 us-gaap Loans Payable
LoansPayable
1766000
CY2021Q4 us-gaap Loans Payable
LoansPayable
2219000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3603000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3911000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8711000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
21000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2474000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2648000
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
16554000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8799000
CY2022Q1 us-gaap Liabilities
Liabilities
47782000
CY2021Q4 us-gaap Liabilities
Liabilities
36453000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
317135000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
393925000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5267000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4780000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240734000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222766000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
147929000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
89592000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
195711000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126045000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1445000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5301000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16620000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20164000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4972000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4309000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
21592000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
24473000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-20147000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19172000
CY2022Q1 hook Grant Income
GrantIncome
1887000
CY2021Q1 hook Grant Income
GrantIncome
2204000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
CY2022Q1 us-gaap Interest Expense
InterestExpense
243000
CY2021Q1 us-gaap Interest Expense
InterestExpense
219000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
528000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-58000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2179000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1934000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17968000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17238000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-17968000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-17238000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-487000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-476000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18455000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17714000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
89592000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 hook Adjustments To Additional Paid In Capital At Market Issuance Cost
AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost
142000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-487000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1621000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-17968000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
147929000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
156123000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1521000
CY2022Q1 hook Increase Decrease In Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
9000
CY2021Q1 hook Increase Decrease In Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
-263000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1078000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
110000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-476000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
125000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1521000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-17238000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-421000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-466000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
140055000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-17968000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-17238000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1621000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1103000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-74000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6075000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1055000
CY2022Q1 hook Increase Decrease In Receivable Research Incentives
IncreaseDecreaseInReceivableResearchIncentives
1655000
CY2021Q1 hook Increase Decrease In Receivable Research Incentives
IncreaseDecreaseInReceivableResearchIncentives
-942000
CY2022Q1 hook Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
-756000
CY2021Q1 hook Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
-73000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
460000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1267000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1614000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
444000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
14128000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-882000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
581000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1733000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14397000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1828000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
330000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1828000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-330000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
20000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
24000
CY2022Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
29625000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
45688000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
125000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75293000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
75198000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14626000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66912000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143177000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-307000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-406000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
141803000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128145000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022Q1 hook Property And Equipment Additions In Accounts Payable And Accrued Expenses
PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses
504000
CY2021Q1 hook Property And Equipment Additions In Accounts Payable And Accrued Expenses
PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses
398000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
240000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Nature of the business and organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HOOKIPA Pharma Inc. (“HOOKIPA” or the “Company”) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the name of Hookipa Biotech, Inc. under the laws of the State of Delaware in February 2017 as a fully-owned subsidiary of Hookipa Biotech AG. In June 2018, the Company changed its name from Hookipa Biotech, Inc. to HOOKIPA Pharma Inc. and in order to effectuate the change of the jurisdiction of incorporation, the Company acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech GmbH. HOOKIPA is headquartered in New York, with European research and preclinical development operations headquartered in Vienna, Austria. In April 2019, the Company closed its initial public offering (“IPO”) and its common stock started trading on the Nasdaq Global Select Market under the ticker symbol “HOOK”.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities and may not ultimately lead to a marketing approval and commercialization of a product. Even if the Company’s drug development efforts are successful, it is uncertain if and when the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p>
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-18000000.0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-75700000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240700000
CY2022Q1 hook Receivables Tax Research Premium Current
ReceivablesTaxResearchPremiumCurrent
15600000
CY2021Q1 hook Grant Income Incentive Program
GrantIncomeIncentiveProgram
2000000.0
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards and the valuation of current and non-current loans payable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 11, 2020 the World Health Organization designated COVID-19 as a global pandemic. The Company believes the extent of the COVID-19 pandemic’s impact on the Company’s business, results of operations and financial condition has been, and will continue to be driven by many factors, most of which are beyond the Company’s control and ability to forecast. Because of these uncertainties, the Company cannot estimate how long or to what extent the pandemic will impact its operations. The Company’s accounting estimates and assumptions may change over time in response to COVID-19 and the change could be material in future periods. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.</p>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of credit risk and of significant suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the three months ended March 31, 2022 and March 31, 2021 the net proceeds from the Company’s offerings have been deposited in bank accounts with investment grade U.S. financial institutions and have been partially invested in a money market fund. The money market fund, held in U.S. dollars, is primarily invested in U.S. and foreign short-term debt obligations. As of March 31, 2022 and December 31, 2021, the Company’s cash and cash equivalents included smaller amounts of cash balances held in accounts with European banks at the Company’s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2022 and December 31, 2021, respectively, Gilead Sciences, Inc. (“Gilead”) accounted for the majority of the accounts receivable balance. For the three months ended March 31, 2022 and March 31, 2021 Gilead accounted for the majority of the Company’s revenues. No other customers accounted for more than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.</p>
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23731000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22718000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6631000
CY2022Q1 hook Collaborative Arrangement Number Of Preclinical Research Programs
CollaborativeArrangementNumberOfPreclinicalResearchPrograms
2
CY2022Q1 hook Number Of Combined Performance Obligation For Each Research Program
NumberOfCombinedPerformanceObligationForEachResearchProgram
1
CY2022Q1 hook Number Of Research Program Performance Obligations
NumberOfResearchProgramPerformanceObligations
2
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6366000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17100000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16352000
CY2021Q4 hook Receivables Tax Research Premium Current
ReceivablesTaxResearchPremiumCurrent
14300000
CY2022Q1 hook Grant Income Incentive Program
GrantIncomeIncentiveProgram
1700000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1063000
CY2022Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
5141000
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
5011000
CY2022Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3217000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4754000
CY2022Q1 hook Accrued Social Security Contributions Current
AccruedSocialSecurityContributionsCurrent
271000
CY2021Q4 hook Accrued Social Security Contributions Current
AccruedSocialSecurityContributionsCurrent
250000
CY2022Q1 hook Accrued Unearned Grant Income Current
AccruedUnearnedGrantIncomeCurrent
571000
CY2021Q4 hook Accrued Unearned Grant Income Current
AccruedUnearnedGrantIncomeCurrent
693000
CY2021Q4 hook Accrued Sub License Fees
AccruedSubLicenseFees
304000
CY2022Q1 hook Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
3511000
CY2021Q4 hook Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
2165000
CY2022Q1 hook Accrued External General And Administration Expenses
AccruedExternalGeneralAndAdministrationExpenses
895000
CY2021Q4 hook Accrued External General And Administration Expenses
AccruedExternalGeneralAndAdministrationExpenses
629000
CY2021Q4 hook Accrued Expenses For Property And Equipment Acquisitions
AccruedExpensesForPropertyAndEquipmentAcquisitions
7000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
21000
CY2022Q1 hook Other Accrued Expenses And Liabilities Current
OtherAccruedExpensesAndLiabilitiesCurrent
260000
CY2021Q4 hook Other Accrued Expenses And Liabilities Current
OtherAccruedExpensesAndLiabilitiesCurrent
57000
CY2022Q1 hook Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8725000
CY2021Q4 hook Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8880000
CY2022Q1 hook Long Term Loans Payable Gross
LongTermLoansPayableGross
5954000
CY2021Q4 hook Long Term Loans Payable Gross
LongTermLoansPayableGross
6074000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
813000
CY2022Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0075
CY2021Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
0
CY2022Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
0
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2993000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1785000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1176000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
5954000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 hook Register For Resale Of Common Stock From Initial Issuance
RegisterForResaleOfCommonStockFromInitialIssuance
P6M
CY2022Q1 hook Register For Resale Of Common Stock Additional Issuances
RegisterForResaleOfCommonStockAdditionalIssuances
P4M
CY2022Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
70200000
CY2019Q2 hook Share Based Payment Arrangement Option Number Of Common Stock Entitled For Each Option
ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption
1
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0164
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.858
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4231178
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.21
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1640000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
145071
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.50
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10034
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.10
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
67269
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.09
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4298946
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.96
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1688000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2682044
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.80
CY2022Q1 hook Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Used For Calculating Intrinsic Values
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues
2.28
CY2021 hook Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Used For Calculating Intrinsic Values
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues
2.33
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
125000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M18D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1681000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1616902
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
10.86
CY2022Q1 hook Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm
P8Y2M12D
CY2022Q1 hook Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue
7000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1621000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1521000
CY2021Q1 hook Income Tax Benefits Net Operating Losses Incurred
IncomeTaxBenefitsNetOperatingLossesIncurred
0
CY2022Q1 hook Income Tax Benefits Net Operating Losses Incurred
IncomeTaxBenefitsNetOperatingLossesIncurred
0
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
400000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5300000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5700000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
100000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5300000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1700000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3600000
CY2022Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5600000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1700000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3900000
CY2021Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
100000
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.014
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2022Q1 us-gaap Contractual Obligation
ContractualObligation
8100000
CY2022Q1 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
8000000.0
CY2022Q1 hook Licensing Fees Intellectual Property Licenses
LicensingFeesIntellectualPropertyLicenses
300000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-17968000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-17238000
CY2022Q1 hook Weighted Average Number Of Shares Outstanding Basic And Diluted Before Conversion
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion
38603022
CY2021Q1 hook Weighted Average Number Of Shares Outstanding Basic And Diluted Before Conversion
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion
29788284
CY2022Q1 hook Weighted Average Series Convertible Preferred Shares Outstanding Converted Into Common Stock
WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock
1697000
CY2021Q1 hook Weighted Average Series Convertible Preferred Shares Outstanding Converted Into Common Stock
WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock
2978000
CY2022Q1 hook Weighted Average Series One Convertible Preferred Shares Outstanding Converted Into Common Stock
WeightedAverageSeriesOneConvertiblePreferredSharesOutstandingConvertedIntoCommonStock
4740000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45040022
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32766284
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2022Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1000
CY2022Q1 hook Convertible Preferred Stock Shares Issuable Upon Conversion
ConvertiblePreferredStockSharesIssuableUponConversion
1697000
CY2022Q1 hook Convertible Preferred Stock Seriesa One Shares Issuable Upon Conversion
ConvertiblePreferredStockSeriesaOneSharesIssuableUponConversion
15800000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4298946
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3536326

Files In Submission

Name View Source Status
0001558370-22-008855-index-headers.html Edgar Link pending
0001558370-22-008855-index.html Edgar Link pending
0001558370-22-008855.txt Edgar Link pending
0001558370-22-008855-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hook-20220331.xsd Edgar Link pending
hook-20220331x10q.htm Edgar Link pending
hook-20220331x10q_htm.xml Edgar Link completed
hook-20220331xex31d1.htm Edgar Link pending
hook-20220331xex31d2.htm Edgar Link pending
hook-20220331xex32d1.htm Edgar Link pending
hook-20220331_cal.xml Edgar Link unprocessable
hook-20220331_def.xml Edgar Link unprocessable
hook-20220331_lab.xml Edgar Link unprocessable
hook-20220331_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending